SI0998556T1 - Diagnosis and treatment of diseases using anti-t-cell receptor vbeta antibodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein 1 (esrp1) - Google Patents

Diagnosis and treatment of diseases using anti-t-cell receptor vbeta antibodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein 1 (esrp1)

Info

Publication number
SI0998556T1
SI0998556T1 SI9830782T SI9830782T SI0998556T1 SI 0998556 T1 SI0998556 T1 SI 0998556T1 SI 9830782 T SI9830782 T SI 9830782T SI 9830782 T SI9830782 T SI 9830782T SI 0998556 T1 SI0998556 T1 SI 0998556T1
Authority
SI
Slovenia
Prior art keywords
antibodies
diseases
esrp1
peptides
diagnosis
Prior art date
Application number
SI9830782T
Other languages
English (en)
Slovenian (sl)
Inventor
Arpi Matossian-Rogers
Original Assignee
Arpi Matossian-Rogers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9715281A external-priority patent/GB2327423B/en
Priority claimed from GBGB9810676.8A external-priority patent/GB9810676D0/en
Application filed by Arpi Matossian-Rogers filed Critical Arpi Matossian-Rogers
Publication of SI0998556T1 publication Critical patent/SI0998556T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
SI9830782T 1997-07-21 1998-07-20 Diagnosis and treatment of diseases using anti-t-cell receptor vbeta antibodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein 1 (esrp1) SI0998556T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9715281A GB2327423B (en) 1997-07-21 1997-07-21 Ligands, including antibodies, showing reactivity against endocrine cells for use in therapy and diagnosis
GBGB9810676.8A GB9810676D0 (en) 1998-05-18 1998-05-18 Ligands including antibodies showing reactivity against endocrine cells for use in therapy and diagnosis
EP98935160A EP0998556B1 (de) 1997-07-21 1998-07-20 Diagnose und behandlung von krankheiten mittels anti-t-zell rezeptor-vbeta-antikörper oder peptide, an denen diese antikörper spezifisch binden, und esrp1
PCT/GB1998/002151 WO1999005175A2 (en) 1997-07-21 1998-07-20 Diagnosis and treatment of diseases using anti-anti-t-cell receptor vbeta anti-bodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein i (esrp1)

Publications (1)

Publication Number Publication Date
SI0998556T1 true SI0998556T1 (en) 2005-10-31

Family

ID=26311906

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9830782T SI0998556T1 (en) 1997-07-21 1998-07-20 Diagnosis and treatment of diseases using anti-t-cell receptor vbeta antibodies or peptides which are recognized by said antibodies, and endocrine secretion regulatory protein 1 (esrp1)

Country Status (21)

Country Link
US (2) US6689359B1 (de)
EP (2) EP1595951A1 (de)
JP (1) JP2002511765A (de)
KR (2) KR100567277B1 (de)
CN (1) CN1330754C (de)
AT (1) ATE297983T1 (de)
AU (1) AU758455B2 (de)
BR (1) BR9810118A (de)
CA (1) CA2296842C (de)
CU (1) CU23412A3 (de)
DE (1) DE69830588T2 (de)
DK (1) DK0998556T3 (de)
EA (1) EA003131B1 (de)
ES (1) ES2245034T3 (de)
IL (3) IL133277A0 (de)
NZ (1) NZ501424A (de)
PL (1) PL204503B1 (de)
PT (1) PT998556E (de)
SI (1) SI0998556T1 (de)
TR (1) TR200000181T2 (de)
WO (1) WO1999005175A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1366901A (en) * 1999-09-23 2001-04-24 Rigel Pharmaceuticals, Inc. Traf4 associated cell cycle proteins, compositions and methods of use
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AU2012241141B2 (en) * 2005-08-11 2015-08-20 Arpi Matossian-Rogers TCR-V-beta related peptides for treatment and diagnosis of autoimmune disease
GB2429013C (en) 2005-08-11 2012-11-28 Arpi Matossian-Rogers Peptides for treatment and diagnosis of autoimmunedisease
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
CN102898519B (zh) 2005-11-30 2015-10-28 Abbvie公司 抗淀粉样β蛋白的单克隆抗体及其用途
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
WO2009048539A2 (en) 2007-10-05 2009-04-16 Genentech, Inc. Monoclonal antibody
EP2558494B1 (de) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta-bindende proteine
NZ606357A (en) 2010-07-30 2015-05-29 Genentech Inc Safe and functional humanized anti beta-amyloid antibody
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
SI2761065T1 (en) * 2011-09-29 2018-02-28 Cellsnap, Llc Ingredients and procedures for toxicity testing

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2072356A1 (en) 1989-12-29 1991-06-30 James L. Urban Diagnosis and treatment of diseases
US5216132A (en) * 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
JPH06507384A (ja) 1991-01-22 1994-08-25 ザ　イミューン　レスポンス　コーポレイション 特定のｔ細胞群による病理的応答により生じる疾患に対するワクチン投与および方法
US5480895A (en) * 1991-09-27 1996-01-02 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof
US5891623A (en) * 1992-11-09 1999-04-06 Consorzio Per Le Biotecnologie Diagnosis and treatment of AIDS onset
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5589328A (en) * 1994-08-04 1996-12-31 Mahant; Vijay K. Chemiluminescence assays based on indoxyl substrates, thioindoxyl substrates and other substrates

Also Published As

Publication number Publication date
PT998556E (pt) 2005-09-30
WO1999005175A3 (en) 1999-06-10
CA2296842C (en) 2012-03-20
CN1264426A (zh) 2000-08-23
US6689359B1 (en) 2004-02-10
CA2296842A1 (en) 1999-02-04
NZ501424A (en) 2005-08-26
EA200000146A1 (ru) 2000-10-30
EP1595951A1 (de) 2005-11-16
CU23412A3 (es) 2009-09-08
PL204503B1 (pl) 2010-01-29
PL338449A1 (en) 2000-11-06
IL176076A0 (en) 2006-10-05
AU758455B2 (en) 2003-03-20
DK0998556T3 (da) 2005-10-17
IL133277A0 (en) 2001-04-30
US20050100541A1 (en) 2005-05-12
JP2002511765A (ja) 2002-04-16
KR100670070B1 (ko) 2007-01-19
BR9810118A (pt) 2000-08-08
EP0998556B1 (de) 2005-06-15
AU8451798A (en) 1999-02-16
KR20010022063A (ko) 2001-03-15
DE69830588D1 (de) 2005-07-21
KR100567277B1 (ko) 2006-04-05
EA003131B1 (ru) 2003-02-27
KR20050046825A (ko) 2005-05-18
CN1330754C (zh) 2007-08-08
EP0998556A2 (de) 2000-05-10
ES2245034T3 (es) 2005-12-16
DE69830588T2 (de) 2006-05-04
WO1999005175A2 (en) 1999-02-04
IL133277A (en) 2006-09-05
TR200000181T2 (tr) 2000-05-22
IL176076A (en) 2010-06-16
ATE297983T1 (de) 2005-07-15

Similar Documents

Publication Publication Date Title
IL176076A0 (en) Ligands,including antibodies showing, reactivity against endocrine cells
HK1021025A1 (en) Process for in vitro detecting the presence or absence of antibodies to anti-tissue transglutinase from body fluids.
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
KR910002897A (ko) 에리트로포이에틴(epo)펩타이드 및 이에 대한 항체
BR0112602A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
MX9801687A (es) Compuestos y metodos para el diagnostico de tuberculosis.
IE890853L (en) Monoclonal Antibodies
ATE421531T1 (de) Apoptose-bezogene verbindungen und deren verwendung
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
CA2344590A1 (en) Treatment of inflammatory disease
DK0687180T3 (da) Fremgangsmåde til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-anti
WO2001096372A3 (en) Zinc transporters proteins and their use in medicinal preparations
NO962596L (no) Nytt tumorsupressorgen
WO2002088378A3 (en) 66784, a novel human potassium channel and uses therefor
FI950962A (fi) Menetelmä anti-DNA-vasta-aineiden toteamiseksi, diagnostinen menetelmä, reagenssipakkaus ja lääkeaine autoimmuunisairauksia varten
WO1999051725A3 (en) Assay for the diagnosis of schizophrenia based on a new peptide
CA2140091A1 (en) Peptides and antisera for detecting human cyclooxygenase-1 and cyclooxygenase-2
WO1998041538A3 (en) Novel human cytokine/steroid receptor protein
WO2002026958A3 (en) Human neprilysin protease
NO941458L (de)
AU2003215667A1 (en) Diagnostic and therapeutic use of human maguin proteins and nucleic acids for neurodegenerative diseases
WO2001066746A3 (en) G-protein coupled receptor related polypeptides